Photoreceptor cGMP phosphodiesterases (PDE6 family) are modular enzymes with each catalytic subunit containing two N-terminal regulatory GAF domains, GAF A and GAF B. The GAF A domains contribute to dimerization of the PDE6 catalytic subunits and to binding of the inhibitory Pc subunits, and represent candidate sites for noncatalytic binding of cGMP. We performed a mutational analysis of selected residues from the GAF A domain of cone PDEa 0 to identify the cGMP-binding pocket and delineate the Pc-binding surface. Results of this analysis establish the noncatalytic cGMP-binding site within the PDE6 GAF A domain and suggest that occupation of the pocket by cGMP is required for high-affinity binding of Pc to the proximate contact surface. Ó 2004 Elsevier Ltd. All rights reserved.
Introduction
Phosphodiesterases of cyclic nucleotides are critical enzymes modulating cellular levels of cAMP and cGMP. Eleven families of PDEs have been identified in mammalian tissues based on primary sequence, substrate selectivity, and regulation (Beavo, 1995; Francis, Turko, & Corbin, 2001) . Photoreceptor rod and cone PDEs comprise the PDE6 family. Rod PDE6 is composed of two large homologous catalytic a-and b-subunits of similar size and two copies of a small inhibitory c-subunit (Baehr, Devlin, & Applebury, 1979; Deterre, Bigay, Forquet, Robert, & Chabre, 1988; Hurley & Stryer, 1982; Lipkin et al., 1990) . Cone PDE is a catalytic homodimer between two PDEa 0 subunits each complexed with a cone-specific Pc subunit (Hamilton & Hurley, 1990; . PDE6s are the effector enzymes in the vertebrate visual transduction cascade. The pool of the GTP-bound transducin-a (Gta) is generated from heterotrimeric Gtabc following its interaction with photoexcited rhodopsin or cone pigments. PDE6s are then activated by GtaGTP that interacts with the holoenzyme and releases the inhibition exerted by the Pc subunits (Arshavsky, Lamb, & Pugh, 2002; Chabre & Deterre, 1989) .
The catalytic domains of PDE6 of about 280 aa residues are located in the C-terminal part of the molecule and are highly conserved among all known cyclic nucleotide phosphodiesterases (Beavo, 1995) . The N-terminal domains of PDE6 catalytic subunits contain two structural motifs termed GAF domains (GAF A and GAF B) because of their presence in cGMP-regulated PDE, adenylyl cyclases, and the E. coli protein Fh1A (Aravind & Ponting, 1997) . In three of the GAF-containing PDE families, cGMP-stimulated PDE2, cGMP-binding/cGMP-specific PDE5, and PDE6, noncatalytic binding of cGMP to the regulatory N-terminal domains had been demonstrated experimentally (Gillespie & Beavo, 1989; Martins, Mumby, & Beavo, 1982; Thomas, Francis, & Corbin, 1990; Yamazaki, Bartucca, Ting, & Bitensky, 1982) . Noncatalytic cGMPbinding has been shown to stimulate the catalytic activity of PDE2 and PDE5 (Martins et al., 1982; Rybalkin, Rybalkina, Shimizu-Albergine, Tang, & Beavo, 2003) . In contrast, the functional significance of the PDE6 GAF domains is not well understood. In PDE6, cGMP bound to noncatalytic sites appears to enhance affinity of the interaction between Pc and the catalytic subunits, but does not influence the catalytic activity independently of Pc binding. Reciprocally, Pc binding enhances cGMP-binding affinity to the GAF domains (Cote, Bownds, & Arshavsky, 1994; Mou & Cote, 2001; Yamazaki et al., 1982) . Although the regions of noncatalytic cGMP binding in PDE2, PDE5, and PDE6 have been approximated from sequence analyses and biochemical experiments, until recently the exact locations of the binding pockets have not been known. A solution of the crystal structure of PDE2A GAF A-GAF B domains provided a critical breakthrough by revealing the cGMP-binding site within the PDE2 GAF B domain and uncovering a novel cGMP-binding motif (Martinez et al., 2002) . Furthermore, the structure made possible the prediction that the GAF A rather than GAF B domains are the likely candidates for noncatalytic cGMPbinding in PDE5 and PDE6 (Martinez et al., 2002) . Recent studies have supported this prediction for PDE5 (Liu, Underwood, Li, Pamukcu, & Thompson, 2002; Sopory, Balaji, Srinivasan, & Visweswariah, 2003) . However, the identity of noncatalytic binding sites in PDE6 has not yet been established. Besides harboring potential cGMP-binding sites, the GAF A domains of PDE6 have also been implicated in binding Pc. Two regions of Pc are mainly involved in the interaction with the PDE6 catalytic subunits, the central polycationic region (residues 21-45 of rod Pc) and the Pc C-terminus. The C-terminus of Pc represents the key inhibitory domain and apparently directly occludes the catalytic cavity (Granovsky & Artemyev, 2000) . The polycationic region makes a major contribution to the overall affinity of Pc for PDE6 catalytic subunits (Artemyev & Hamm, 1992; Mou & Cote, 2001) . A cross-linking study using a photoexcitable peptide probe corresponding to the polycationic region of Pc revealed incorporation of the probe into the GAF A domain of rod PDE6a at residues Met 138 Gly 139 (Muradov, Granovsky, Schey, & Artemyev, 2002) . This led us to hypothesize that the positive cooperativity between noncatalytic cGMP and Pc results from their binding to the same regulatory domain. We carried out a mutational analysis of potential cGMP-and Pc-contact residues within the GAF A domain of cone PDEa 0 to delineate the binding sites and elucidate the molecular mechanism of their cooperativity.
Materials and methods

Materials
[ 3 H]cGMP was a product of Amersham Pharmacia Biotech. All restriction enzymes were purchased from NEB. AmpliTaq DNA polymerase was a product of Applied Biosystems, and Pfu DNA polymerase was a product of Stratagene. Polyclonal anti-His6 antibodies were obtained from Santa Cruz. Zaprinast and all other reagents were purchased from Sigma.
Mutagenesis of Chi16
The C-terminally His6-tagged PDE5/PDE6 Chi16 (Granovsky & Artemyev, 2000) was constructed as follows. The Chi16 sequence was amplified from the pFastBacHTb-Chi16 plasmid using a 5 0 primer containing an RsrII site and a 3 0 primer containing His6-tag, a stop codon, and a XhoI site. This sequence was then subcloned into the RsrII/XhoI digested pFastBacHTb. Mutations were introduced into Chi16 by PCR-directed mutagenesis using a 5 0 primer coding desired substitution and a 3 0 primer containing the SacI site (aa Glu 248 -Leu 249 ). This PCR product was then extended to the start of Chi16 using PCR with a 5 0 primer containing RsrII site. Resulting PCR products were cut with RsrII and SacI and ligated to similarly digested pFastBacHTb-Chi16. The sequences of all mutants were verified by automated DNA sequencing at the University of Iowa DNA Core Facility.
Expression and purification of Chi16 and mutants
Generation of the recombinant bacmid DNAs, transfection of Sf9 cells, and viral amplifications were carried out according to the manufacturerÕs recommendations (Life Technologies, Inc.). For protein expression, Sf9 cell cultures (3 · 10 6 cells/ml) were infected with baculoviruses at MOI of 2-5. Cells were harvested by centrifugation at 48 h after infection; washed with 20 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl and 4 mM MgSO 4 , and processed immediately or stored at À80°C until use. Sf9 cell pellets from 100 ml culture were resuspended in 10 ml of 20 mM Tris-HCl buffer (pH 8.0) containing 2 mM MgSO 4 , and one tablet of Complete Mini protease inhibitor cocktail (Roche Molecular Biochemicals). Cell lysates were obtained by sonication with four 20-s pulses using a flat tip attached to a 550 Sonic Dismembrator (Fisher Scientific) and cleared by centrifugation (100,000g, 90 min, 4°C).
Chi16 and mutants were partially purified using affinity chromatography on a His-bind resin (Novagen) as described earlier (Granovsky & Artemyev, 2000) . Purified proteins were dialyzed against 40% glycerol and stored at À20°C.
cGMP-binding assay
Chi16 and its mutants were incubated on ice for 10 min in a volume of 150 ll of 30 mM Tris-HCl (pH 8.0), 50 mM NaCl, 1 mM EDTA, 5 mM 2-mercaptoethanol, and 0.1 mM zaprinast. These mixtures then were added to tubes containing 50 ll [ 3 H]cGMP (100,000 cpm) and differing concentrations of nonradioactive cGMP. After 20 min incubation on ice, samples were applied to wet 0.45 lm nitrocellulose membrane filters, and were washed 5 times with 1 ml ice-cold PBS buffer containing 1 mM EDTA. Dried filters were dissolved in scintillation cocktail and were counted in a scintillation counter. The data were fit to equation
2.5. PDE activity assay PDE activity was measured using [ 3 H]cGMP as described (Natochin & Artemyev, 2000) . Briefly, 0.1 nM Chi16 or mutants were incubated in 80 ll of 20 mM Tris-HCl (pH 8.0) buffer containing 50 mM NaCl, 1 mM MgSO 4 , and 2 mM 2-mercaptoethanol, 0.1 lm bacterial alkaline phosphatase, 5 lM [ 3 H]cGMP (100,000 cpm) at 25°C. After addition of [ 3 H]cGMP, the reaction was allowed to proceed for 10 min, and was stopped by the addition of AG1-X2 anion exchange resin (0.5 ml of 20% bed volume suspension). Samples were incubated for 10 min at 25°C with occasional mixing and spun at 9000g for 2 min. Aliquots of 0.25 ml were removed for counting in a scintillation counter. To determine K m values for cGMP, PDE activity was measured using 0.5-100 lM cGMP and the data were fit to equation 
, where T (top) is PDE activity in the absence of Pc (or zaprinast), B (bottom) is PDE activity at an infinite concentration of Pc (or zaprinast), and X is the logarithm of total Pc (or zaprinast) concentration.
Other methods
Western blot analysis of proteins was performed following SDS-PAGE in 10% gels. Chi16 and mutants were detected using anti-His6 polyclonal antibodies (Santa Cruz) (dilution 1:3000), anti-rabbit antibodies conjugated to horseradish peroxidase (Sigma), and ECL reagents (Amersham Biosciences). Protein concentrations were determined by the method of Bradford (1976) using IgG as a standard. The molar concentrations of Chi16 and mutants were calculated based on the fraction of PDE protein in preparations and the MW of 186.0 kDa for the catalytic dimers. The fractional concentrations of PDE were determined by scanning Coomassie Blue stained SDS gels and measuring integrated densities of individual bands with Scion Image software (v. Beta 4.0.2). A typical fraction of Chi16 and mutants in partially purified preparations was 20-30%.
Results
Mutagenesis of potential Pc-contact residues within GAF A domain of PDE6a
0
Identification of PDE6a Met
138 Gly 139 as the site of specific cross-linking of Pc-21-45 to rod PDE6 suggests that the polycationic region of Pc binds in the vicinity of these residues (Muradov et al., 2002) . Moreover, analysis of inhibition chimeric PDE5/PDE6 enzymes by Pc indicates that the interaction with Pc-21-45 is specific to the GAF domains of photoreceptor PDEs (Granovsky & Artemyev, 2000) . Therefore, only PDE6-conserved residues that differ with corresponding PDE5 residues have been considered for mutational analysis. Additional criteria for the selection were a solvent accessibility of >25% and a proximity of <15 Å to the PDE6aMet 138 counterpart, PDE6a 0 Val 135 , using a homology model of the PDE6a 0 GAF A domain (Fig.  1) . The GAF B domain of PDE2 was used in the modeling because it has higher degree of homology to the PDE6 GAF A domain than the PDE2 GAF A domain (Fig. 1A) 1A and B) . These mutations were introduced into the improved template of the Pc-sensitive chimera Chi16 containing PDE6a 0 GAF domains (Granovsky & Artemyev, 2000) . The improvement was in the C-terminal position of His6-tag, which led to increased expression levels using Baculovirus/Sf9 cell system and consistent yields of mutant proteins following purification over His-Bind resin. All seven mutants were expressed at comparable levels as determined by Western blotting (Fig. 2A) .
The catalytic properties (Table 1 ) of the mutant PDEs were similar to those of Chi16 (K m 3.6 lM; k cat 7 s À1 ) indicating that the substitutions within the GAF A domain did not affect the catalytic domain. Furthermore, the mutants displayed no significant differences in the IC 50 values for inhibition by zaprinast, a PDE5/ PDE6 competitive inhibitor (Table 1) . Binding of cGMP to noncatalytic sites in all seven mutants was intact, supporting proper folding of the GAF domains (Table 1) . The Pc-inhibition tests, however, revealed that two out of seven mutations, V130A and H158A, considerably impaired the interaction with the inhibitory subunit (Fig. 3, Table 1 ). The remaining substitutions had no significant effect on the ability of Pc to inhibit Chi16 (Table 1) .
Identification of the noncatalytic cGMP-binding pocket of PDE6a
0
The novel cGMP-binding motif identified in the PDE2 GAF B domain is comprised of 11 aa residues (Martinez et al., 2002) . The structural determinants of the cGMP-binding pocket identified in the PDE2 GAF B domain are better preserved in the PDE6 GAF A domain. On this basis, the GAF A domain Fig. 1. (A) Sequence alignment of the bovine PDE6 and PDE5 GAF A domains with the GAF B domain of mouse PDE2A. The a1 helices in GAF A domains, which correspond to the connecting helix between GAF A and GAF B (Martinez et al., 2002) , are omitted from the alignment and modeling. Red arrow indicates position of the cross-linked residue PDE6aMet 138 (Muradov et al., 2002) . Positions corresponding to cGMP-binding residues in the PDE2 GAF B domain are underlined (Martinez et al., 2002) . Green arrows indicate candidate cGMP-binding residues selected for mutagenesis of PDE6a 0 GAF A. (B) A homology model of the PDE6a 0 GAF A domain was generated with Swiss-PdbViewer (v. 3.7b2) and SWISS-MODEL (Schwede et al., 2003) using the coordinates of the PDE2A GAF B domain as a template (Martinez et al., 2002) and the sequence alignment shown in Fig. 1A . A space-filling image is produced using RasMol (v. 2.6). Potential Pc-contact residues in the vicinity of Val 135 (red) (PDE6a 0 counterpart of PDE6aMet 138 ) selected for mutagenesis are shown in blue. (For interpretation of the references in colour in this figure legend, the reader is referred to the web version of this article.) of PDE6 was favored to form a noncatalytic cGMPbinding site (Martinez et al., 2002) . The alignment of PDE6 GAF A domains with the PDE2 GAF B domain and the model of the PDE6a 0 GAF A domain with cGMP docked in the anti-conformation (Figs. 1 and 6) were used to select candidate residues for noncatalytic cGMP-binding. Six residues, Ser 92 , Leu 110 , Asp 164 , Thr 167 , Thr 171 , and Met 190 , were selected to potentially represent different types of interactions (hydrophobic contacts, hydrogen bonds) with different groups of cGMP (the guanine ring and ribose). Two mutants, T171A and M190A, were expressed at significantly reduced levels in comparison to Chi16 and the other mutants, suggesting important roles of these residues in correct folding of the GAF A domains. Although these mutants were catalytically active, they displayed no detectable binding of noncatalytic cGMP (not shown). S92A, L110A, D164A, and T167A were expressed comparably to Chi16 (Fig. 2B) . The catalytic characteristics of these mutant PDEs were not considerably different from those of Chi16 (Table 1) . The IC 50 values for the inhibition of mutants by zaprinast were also similar (Table 1 ). In contrast, the affinity and stoichiometry of noncatalytic cGMP-binding were significantly lower for two Chi16 mutants, L110A and D164A (Fig. 4, Table 1 ). The K d value for cGMP-binding to L110A was 84 nM with the calculated maximal binding of 55% of that for Chi16. The impairment of cGMP-binding to D164A was even more severe with the K d value of 233 nM and the maximal binding of 45%. Substitution of Ser 92 had a moderate effect on the Chi16 affinity for cGMP (Fig.  4) , whereas the T167A mutation produced no change (Table 1) . , and Thr 167 (B). Recombinant His6-tagged mutants were expressed in Sf9 cells and partially purified using chromatography on a His-Bind resin (Novagen) as described under ''Experimental procedures''. Immunoblotting was performed using rabbit anti-His6 polyclonal antibodies. Table 1 Properties of the GAF A domain mutants of Chi16
IC 50 for zaprinast, nM
Chi16 mutants with substitutions of potential Pc-contact residues 
Mutations affecting noncatalytic cGMP binding to the GAF A domain impair the PDE inhibition by Pc
Identification of the GAF A domain mutants with diminished noncatalytic binding of cGMP allowed us to test if these substitutions influenced the interaction with Pc. The analysis of inhibition of PDE activity of L110A and D164A by Pc demonstrated markedly increased K i values (Fig. 5) . Two mutations, S92A and T167A, did not significantly alter the inhibition by Pc (Table 1) . In a reciprocal approach, we attempted to investigate the potential effects of Pc on noncatalytic cGMP-binding to Chi16 and its mutants. However, Chi16, unlike native cone PDE6, did not display strong potentiation of cGMP-binding by Pc. The affinity of Chi16 for noncatalytic cGMP (Table 1) appears to be significantly higher than that of cone PDE (Granovsky et al., 1998) , and only modest ($15%) increases in the binding of cGMP to Chi16 and D164A were detected in the presence of 2 lM Pc (not shown).
Discussion
The direct role of the noncatalytic cGMP-binding to the GAF domains in regulating PDE catalytic activity has been demonstrated for enzymes from the PDE2 and PDE5 families. The roles and mechanisms of PDE6 GAF domains in regulation of the enzyme remain largely obscure. Several factors contributed to the lack of full understanding of the function of the PDE6 GAF domains. First, achieving an effective expression system for the wild-type PDE6 enzymes had been difficult (Piriev, Yamashita, Shih, & Farber, 2003; Qin & Baehr, 1994) and mutagenesis of PDE6 residues has primarily been performed using PDE5/PDE6 chimeras (Granovsky & Artemyev, 2000; Granovsky et al., 1998) . Secondly, noncatalytic cGMP-binding by PDE6 is complex in that the binding properties of the rod and cone enzymes are different (Gillespie & Beavo, 1988 . Furthermore, significant variations had been reported in cGMP-binding characteristics of mammalian and amphibian PDE6 (Gillespie & Beavo, 1989; Yamazaki et al., 1982) . Despite all the variations, the key regulation mode--a positive cooperativity between noncatalytic cGMP-binding and the binding of Pc--appears to be common for various PDE6 isoforms (Cote et al., 1994; Mou & Cote, 2001; Yamazaki et al., 1982) . Pc binding enhances cGMP-binding affinity for the GAF domains. Reciprocally, an occupation of GAF domains by cGMP increases the Pc affinity for the catalytic subunits. It has been suggested that a decrease in intracellular cGMP upon light stimulation and/or light adaptation of photoreceptor cells may cause dissociation of cGMP from the noncatalytic sites of PDE6. A subsequent reduction in Pc affinity for PDE6 could promote a concerted GAP action of RGS9 and Pc on Gta, thereby accelerating the turnoff of visual signal (Cote et al., 1994; Mou & Cote, 2001) . Understanding the mechanism of positive cooperativity between noncatalytic cGMP and Pc may provide insights into functional roles of the regulatory domains of PDE6. Others and we have demonstrated that the polycationic region of Pc is responsible for PcÕs ability to enhance cGMP affinity for the PDE6 GAF domains (Granovsky et al., 1998; Mou & Cote, 2001) . Identification of PDE6a Met 138 Gly 139 as the site of specific cross-linking of Pc-21-45 to rod PDE6 suggests that the PDE6 GAF A domains directly participate in binding of the polycationic region of Pc (Muradov et al., 2002) . The interaction of Pc-21-45 with the GAF A domains of PDE6 and the stimulatory effect of Pc on noncatalytic cGMP-binding is consistent with the GAF A domains being the functional cGMP-binding sites as predicted by the structure of the PDE2 GAF domains (Martinez et al., 2002) . The mutational analysis of the PDE6a 0 GAF A domain in the contexts of chimeric PDE5/ PDE6 enzyme confirmed that it contains the Pc-binding site. The analysis also provided the first experimental evidence that the PDE6a 0 GAF A domain forms a binding pocket for noncatalytic cGMP. Mutations of two potential cGMP-contact residues, Thr 171 and Met 190 , resulted in a total loss of the cGMP binding. From the model of PDE6a 0 GAF A, both residues are predicted to interact with the phospho-ribose moiety of cGMP (Fig. 6 ). This finding would support the localization of the cGMP-binding site. Yet, the folding defects for these two mutants cannot be ruled out. However, characterization of two other mutants, L110A and D164A, establishes the identity of the binding pocket. These mutants are comparable to Chi16 in terms of expression levels and catalytic characteristics, but their noncatalytic cGMP-binding was markedly reduced. Leu 110 is likely to make stacking hydrophobic interactions with the guanine ring of cGMP, whereas Asp 164 is in a position to interact with both the guanine ring and the phospho-ribose portions of cGMP (Fig. 6) . Disruption of these interactions is in agreement with the observed defects in cGMP-binding. Substitution of Phe 205 in PDE5, a counterpart to Leu 110 in Chi16, had also led to a severe cGMP-binding defect in this related enzyme (Sopory et al., 2003) . Mutation of Ser 92 resulted in a moderate decrease of Chi16 affinity for noncatalytic cGMP. Substitution of Thr 167 , another potential contact residue for cGMP, had no significant effect on the ligand binding. Assuming analogous binding of cGMP to PDE2 and PDE6, Thr 167 of PDE6a 0 would make only a watermediated contact with the guanine ring, and thus, the mutant phenotype is not surprising.
Identification of the binding pocket for cGMP and two Pc-interacting residues on the surface of the PDE6a 0 GAF A domain allows a closer examination of the spatial and structural relationships between the two binding sites. The Pc contact residues appear to be situated in remarkable proximity to the opening of the cGMP-binding pocket. This finding supports the hypothesis that the positive cooperativity between cGMP and Pc observed in native PDE6 arises from direct mutual stabilization of the binding sites. The impairment of Pc-inhibition in the mutants lacking high affinity for noncatalytic cGMP reinforces this mechanism. A molecule of cGMP is buried in the binding cavity (Fig. 6) , which presumably adopts a more open conformation prior to binding the nucleotide. In all likelihood, the Pc polycationic region has a low affinity for the ''empty'' conformation of the GAF A domain. Binding of cGMP apparently leads to a conformational switch in the GAF A domain thereby inducing the binding of Pc and further locking the ligand in place. 
